Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of sodium tanshinone IIA sulfonate in preparation of anti-pancreatic fibrosis medicine

A technology for pancreatic fibrosis and tanshinone, applied in the field of medicine

Pending Publication Date: 2022-05-27
中国人民解放军海军军医大学第一附属医院
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, whether tanshinone IIA sodium sulfonate as a prescription drug also has anti-pancreatic fibrosis effect and what its mechanism is has not been reported in the relevant literature.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of sodium tanshinone IIA sulfonate in preparation of anti-pancreatic fibrosis medicine
  • Application of sodium tanshinone IIA sulfonate in preparation of anti-pancreatic fibrosis medicine
  • Application of sodium tanshinone IIA sulfonate in preparation of anti-pancreatic fibrosis medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] Example 1: Therapeutic effect of tanshinone IIA sodium sulfonate on cerulein-induced chronic pancreatitis and pancreatic fibrosis model mice (in vivo experiment)

[0043] The methods of grouping mice and making models are as follows:

[0044] C57BL / 6N male mice, 6-8 weeks old, body weight 20±2g, provided by Beijing Weitong Lihua Laboratory Animal Technology Co., Ltd. The used sodium tanshinone IIA sulfonate was produced by Shanghai No. 1 Biochemical Pharmaceutical Co., Ltd., trade name: Nuoxinkang.

[0045] The temperature of the rearing room is 18-22°C, the relative humidity is 60%-75%, and the mice are fed with SPF grade chow.

[0046] Random grouping, 3 rats in each group: normal group, model group (Cae), low-dose group (Cae+STS 5mg / kg·d), middle-dose group (Cae+STS 10mg / kg·d), high-dose group (Cae+STS 20 mg / kg·d).

[0047] Specific administration method (Fig. 1A): In the normal group, 0.1 ml of PBS buffer was injected intraperitoneally, once a day. The mice in t...

Embodiment 2

[0061] Example 2: Tanshinone IIA sodium sulfonate can inhibit the activity of human pancreatic stellate cells (HPSCs) (in vitro experiment).

[0062] The specific method is as follows:

[0063] The HPSCs used in this study were purchased from Shanghai Hexu Biotechnology Co., Ltd. The used sodium tanshinone IIA sulfonate was produced by Shanghai No. 1 Biochemical Pharmaceutical Co., Ltd., trade name: Nuoxinkang. The CCK-8 reagent used was produced by DOJINDO, Japan. TGF-β1 cytokines were purchased from American R&D Company.

[0064] (2) Research steps:

[0065] ① The HPSCs were divided into the normal group, the TGF-β1 group and the tanshinone IIA sodium sulfonate-treated group. The normal group was only treated with DMEM medium containing 10% fetal bovine serum, and the TGF-β1 group and the drug-treated group were treated with transforming growth factor β1. (TGF-β1) at a dose of 10 ng / ml (diluted in the above medium) to stimulate HPSCs for 48 hours and then activate them. ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of medicines, in particular to application of sodium tanshinone IIA sulfonate in preparation of a medicine for resisting pancreatic fibrosis. The application has the advantages that a novel medical application is provided for the prescription medicine tanshinone IIA sodium sulfonate, and a novel clinical treatment means is provided for pancreatic fibrosis.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to the application of tanshinone IIA sodium sulfonate in the preparation of anti-pancreatic fibrosis medicaments. Background technique [0002] Chronic pancreatitis is a progressive chronic inflammatory disease of pancreatic tissue caused by many factors such as poor living habits, heredity, and environment. Its pathological features are pancreatic acinar atrophy, destruction and interstitial fibrosis. The main clinical manifestations are recurrent epigastric pain, pancreatic insufficiency, and exocrine insufficiency, which may be accompanied by pancreatic calcification, pancreatic stones, pancreatic cysts, pancreatic duct stenosis or irregular expansion, etc. Pancreatic fibrosis is an important disease development process of chronic pancreatitis. Alcoholism is one of the main causes of chronic pancreatitis and pancreatic fibrosis, accounting for about 20% in my country. For the ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/58A61P1/18
CPCA61K31/58A61P1/18
Inventor 迮兴宇李兆申金晶吴洪玉王丽娟邹文斌廖专
Owner 中国人民解放军海军军医大学第一附属医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products